⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428136 | 1.00 | — | — | |
| SCHEMBL2825761 | 1.00 | — | — | |
| SCHEMBL2825759 | 1.00 | — | — | |
| SCHEMBL641045 | 0.81 | — | — | |
| SCHEMBL22843767 | 0.80 | CTSD (0.41) | — | |
| Hydrochloric Acid SCHEMBL6948108 | 0.79 | — | — | |
| SCHEMBL28062877 | 0.79 | — | — | |
| SCHEMBL28596491 | 0.78 | SLC22A6 (0.43) | — | |
| SCHEMBL8534163 | 0.77 | — | — | |
| SCHEMBL5670925 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459336-B2 | Pyrazine carbamates and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-04 | — | — | US | disclosed |
| EP-3983072-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950357-A | Pyrazine carbamates and their use as GluN2B receptor modulators | 詹森药业有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-11046714-B2 | 2,2-difluorodioxolo A2A receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020249796-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392155-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| EP-3038466-B1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20160214997-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-07-28 | — | — | US | disclosed |
| EP-3038466-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031221-A1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |